Skip to main content

Table 5 Association of HDAC3 expression with various clinicopathological factors

From: Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression

Characteristic

All cases

HDAC 3 low (IRS 0–4)

HDAC 3 intermediate (IRS 6–8)

HDAC 3 high (IRS 9–12)

P-value χ 2-test for trends

All cases

224 (100%)

80 (35.7%)

73 (32.6%)

71 (31.6%)

--

Histological type

    

0.34

Ductal carcinoma/Other

185 (100%)

69 (37.2%)

58 (31.4%)

58 (31.4%)

 

Lobular carcinoma

35 (100%)

10 (28.6%)

12 (34.3%)

13 (37.1%)

 

Histological grade

    

<0.001*

G1

63 (100%)

32 (50.8%)

19 (30.2%)

12 (19%)

 

G2

101 (100%)

33 (32.7%)

35 (34.6%)

33 (32.7%)

 

G3

56 (100%)

14 (25%)

16 (28.6%)

26 (46.4%)

 

Nodal status

    

0.61

negative

133 (100%)

51 (38.3%)

39 (29.3%)

43 (32.4%)

 

positive

78 (100%)

26 (33.3%)

26 (33.3%)

26 (33.3%)

 

pT-Stage

    

0.55

pT1

119 (100%)

43 (36.1%)

37 (31.1%)

39 (32.8%)

 

pT2/pT3

87 (100%)

28 (32.2%)

29 (33.3%)

30 (34.5%)

 

pT4

13 (100%)

7 (53.8%)

4 (30.8%)

2 (15.4%)

 

Hormone receptor status

    

0.04*

Hormone receptor positive

176 (100%)

65 (36.9%)

63 (35.8%)

48 (27.3%)

 

Hormone receptor negative

43 (100%)

14 (32.6%)

7 (16.3%)

22 (51.2%)

 

HER2 status

    

0.12

negative

191 (100%)

71 (37.2%)

63 (35.8%)

48 (27.3%)

 

positive

25 (100%)

8 (32%)

4 (16%)

13 (52%)